دورية أكاديمية
Comparative safety review of antithrombotic treatment options for patients with atrial fibrillation undergoing percutaneous coronary intervention.
| العنوان: | Comparative safety review of antithrombotic treatment options for patients with atrial fibrillation undergoing percutaneous coronary intervention. |
|---|---|
| المؤلفون: | Erbay MI; Division of Cardiovascular Medicine, Cerrahpasa School of Medicine, Istanbul University Cerrahpasa, Istanbul, Turkey.; Department of Cardiology, The Lundquist Institute at Harbor-UCLA Medical Center, Torrance, CA, USA., Pyrpyris N; First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Hippokration General Hospital, Athens, Greece., Susarla S; Department of Cardiology, The Lundquist Institute at Harbor-UCLA Medical Center, Torrance, CA, USA., Ulusan S; Faculty of Medicine, Suleyman Demirel University, Isparta, Isparta Province, Turkey., Mares AC; Division of Cardiovascular Medicine, Yale School of Medicine, Yale University, New Haven CT, USA., Wilson TP; Department of Internal Medicine, St. George's University School of Medicine, True Bule, Greneda., Lee D; Department of Cardiology, The Lundquist Institute at Harbor-UCLA Medical Center, Torrance, CA, USA., Sood A; Department of Medicine, The Wright Center for Graduate Medical Education, Scranton, PA USA., Gupta R; Department of Cardiology, Lehigh Valley Health Network, Allentown, PA USA. |
| المصدر: | Expert opinion on drug safety [Expert Opin Drug Saf] 2024 Feb; Vol. 23 (2), pp. 149-160. Date of Electronic Publication: 2024 Jan 17. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 101163027 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-764X (Electronic) Linking ISSN: 14740338 NLM ISO Abbreviation: Expert Opin Drug Saf Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2015- : Abingdon, Oxford : Taylor & Francis Original Publication: London : Ashley Publications, c2002- |
| مواضيع طبية MeSH: | Atrial Fibrillation*/complications , Atrial Fibrillation*/drug therapy , Percutaneous Coronary Intervention*/adverse effects , Percutaneous Coronary Intervention*/methods, Humans ; Anticoagulants/adverse effects ; Fibrinolytic Agents/adverse effects ; Hemorrhage/chemically induced ; Platelet Aggregation Inhibitors/adverse effects |
| مستخلص: | Introduction: Balancing antithrombotic therapy for atrial fibrillation (AF) patients undergoing percutaneous coronary intervention (PCI) remains a clinical challenge due to coexisting thrombogenic risks. This review emphasizes the delicate balance required to prevent ischemic events while minimizing bleeding complications, particularly in the context of risk assessment. Areas Covered: This review spans from 2010 to October 2023, exploring the complexities of antithrombotic management for AF patients undergoing PCI. It stresses the need for personalized treatment decisions to optimize antithrombotic therapies effectively. Expert Opinion: The evolving evidence supports double antithrombotic therapy (DAT) over triple antithrombotic therapy (TAT) for these patients, showcasing a more favorable safety profile without compromising efficacy. Non-vitamin K antagonist oral anticoagulant (NOAC)-based DAT strategies exhibit superiority in reducing major bleeding events while effectively preventing ischemic events. Recommendations from the 2023 European Society of Cardiology (ESC) Guidelines advocate for NOAC-based DAT post-PCI, endorsing safer antithrombotic profiles.Challenges persist for specific patient categories requiring both oral anticoagulants and antiplatelets, necessitating personalized approaches. Future advances in intravascular imaging and novel coronary stent technologies offer promising avenues to optimize outcomes and influence antithrombotic strategies in AF-PCI patients. |
| فهرسة مساهمة: | Keywords: Atrial fibrillation; anticoagulation; antiplatelets; percutaneous coronary intervention; vitamin K antagonists |
| المشرفين على المادة: | 0 (Anticoagulants) 0 (Fibrinolytic Agents) 0 (Platelet Aggregation Inhibitors) |
| تواريخ الأحداث: | Date Created: 20240112 Date Completed: 20240214 Latest Revision: 20240214 |
| رمز التحديث: | 20240214 |
| DOI: | 10.1080/14740338.2024.2305367 |
| PMID: | 38214282 |
| قاعدة البيانات: | MEDLINE |
PDF full text from Publisher | تدمد: | 1744-764X |
|---|---|
| DOI: | 10.1080/14740338.2024.2305367 |